ProKidney Corp. (NASDAQ:PROK) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC raised its position in ProKidney Corp. (NASDAQ:PROK) by 102.0% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 2,203,934 shares of the company’s stock after buying an additional 1,112,933 shares during the quarter. Geode Capital Management LLC’s holdings in ProKidney were worth $4,232,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. XTX Topco Ltd purchased a new stake in shares of ProKidney in the third quarter valued at approximately $41,000. Intech Investment Management LLC acquired a new position in ProKidney during the third quarter worth $46,000. AQR Capital Management LLC acquired a new stake in ProKidney in the 2nd quarter valued at about $50,000. The Manufacturers Life Insurance Company purchased a new position in ProKidney during the 2nd quarter valued at about $60,000. Finally, Castleview Partners LLC acquired a new position in shares of ProKidney during the 3rd quarter worth approximately $63,000. Hedge funds and other institutional investors own 51.59% of the company’s stock.

ProKidney Trading Up 7.5 %

NASDAQ:PROK opened at $1.86 on Monday. The firm has a market capitalization of $542.49 million, a price-to-earnings ratio of -3.38 and a beta of 1.32. ProKidney Corp. has a twelve month low of $1.18 and a twelve month high of $4.44. The firm’s fifty day simple moving average is $1.82 and its 200 day simple moving average is $2.05.

ProKidney (NASDAQ:PROK) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.14). On average, analysts predict that ProKidney Corp. will post -0.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on PROK. Guggenheim started coverage on shares of ProKidney in a report on Tuesday, September 10th. They set a “buy” rating and a $6.00 price target for the company. JPMorgan Chase & Co. started coverage on ProKidney in a research note on Monday, September 30th. They issued a “neutral” rating on the stock. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $4.50.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.